Abstract
We investigated the molecular and pharmacologic characteristics of VIP receptors on two human SCLC cell lines: NCI-N592 and NCI-H345. With NCI-N592 cell, the order of potency of VIP-related peptides in inhibiting 125I-VIP binding and in stimulating cAMP production was typical of the human VIP receptor. By covalent cross-linking, a polypeptide of Mr 62,300 was obtained. Conversely, the behavior of NCI-H345 cell line was totally different: helodermin was the most potent peptide, VIP and PHI were equipotent, while hGRF and secretin were totally ineffective. These results suggest that NCI-N592 cells possess a typical VIP receptor while NCI-H345 cells possess a helodermin-preferring receptor, and that the natural target of helodermin might not be the VIP receptor.
Publication types
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Carcinoma, Small Cell / metabolism*
-
Cell Membrane / metabolism
-
Cross-Linking Reagents
-
Cyclic AMP / metabolism
-
Electrophoresis, Polyacrylamide Gel
-
Humans
-
Intercellular Signaling Peptides and Proteins
-
Iodine Radioisotopes
-
Lung Neoplasms / metabolism*
-
Peptides*
-
Receptors, Cell Surface / chemistry*
-
Receptors, Gastrointestinal Hormone / chemistry*
-
Receptors, Gastrointestinal Hormone / metabolism
-
Receptors, Neuropeptide*
-
Receptors, Vasoactive Intestinal Peptide
-
Tumor Cells, Cultured
-
Vasoactive Intestinal Peptide / metabolism*
Substances
-
Cross-Linking Reagents
-
Intercellular Signaling Peptides and Proteins
-
Iodine Radioisotopes
-
Peptides
-
Receptors, Cell Surface
-
Receptors, Gastrointestinal Hormone
-
Receptors, Neuropeptide
-
Receptors, Vasoactive Intestinal Peptide
-
helodermin receptor
-
Vasoactive Intestinal Peptide
-
heliodermin
-
Cyclic AMP